Company news

Arcutis Biotherapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 9, 2024

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 4, 2024

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 2, 2024

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

May 12, 2024

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

April 28, 2024

Arcutis Appoints David Topper as Chief Financial Officer

April 9, 2024

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 27, 2024

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

March 10, 2024

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

March 9, 2024

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

March 3, 2024

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

March 3, 2024

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

February 28, 2024

Arcutis Announces Proposed Public Offering

February 27, 2024

Arcutis Announces Pricing of $150 Million Public Offering

February 27, 2024

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

February 27, 2024

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 26, 2024

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

January 30, 2024

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

January 28, 2024

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

January 21, 2024

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

January 13, 2024

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

January 13, 2024

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

December 14, 2023

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

November 28, 2023

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

November 2, 2023

Arcutis to Report Third Quarter 2023 Financial Results

October 24, 2023

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

October 19, 2023

Arcutis Announces Pricing of $100 Million Public Offering

October 18, 2023

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

October 12, 2023

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

October 5, 2023

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

September 26, 2023

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

September 24, 2023

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

September 18, 2023

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

September 11, 2023

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

September 6, 2023

Arcutis to Present at Upcoming Investor Conference

September 4, 2023

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

August 30, 2023

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%

August 28, 2023

Arcutis Appoints Interim Chief Financial Officer (CFO)

August 17, 2023

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

August 9, 2023

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023

Arcutis to Report Second Quarter Financial Results

July 23, 2023

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

July 16, 2023

Arcutis Announces Leadership Transition

May 23, 2023

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

May 1, 2023

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

April 27, 2023

Arcutis to Report First Quarter Financial Results

April 24, 2023

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

April 17, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 27 decks. Every deck is listed under its year.